Hu Mimi I
Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1461, Houston, TX 77030, USA.
Endocrinol Metab Clin North Am. 2021 Dec;50(4):721-728. doi: 10.1016/j.ecl.2021.07.003.
Hypercalcemia of malignancy (HCM) is considered an oncologic emergency associated with significant symptom burden and increased comorbid conditions and mortality. Underlying pathologic processes most often stimulate osteoclast-mediated bone resorption. Although long-term control of HCM depends on effective management of the underlying cancer, temporizing management strategies for acute and/or symptomatic HCM include hydration and antiresorptive bone-modifying agents. Although most patients respond well to the antiresorptive therapies available, further investigation into other agents for those who are refractory to both bisphosphonates and denosumab is needed.
恶性肿瘤高钙血症（HCM）被视为一种肿瘤急症，伴有显著的症状负担、合并症增加及死亡率上升。潜在的病理过程最常刺激破骨细胞介导的骨吸收。尽管HCM的长期控制取决于对潜在癌症的有效管理，但针对急性和/或有症状HCM的临时管理策略包括补液和抗吸收性骨改良剂。虽然大多数患者对现有的抗吸收治疗反应良好，但对于那些对双膦酸盐和地诺单抗均难治的患者，仍需要进一步研究其他药物。
